AURX (Nuo Therapeutics) Beta: -0.1550 (As of Jun. 26, 2026)


AURX Nuo Therapeutics Inc AURX
33 GF Score
Price $1.01
GF Value $4.23
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nuo Therapeutics Beta?

Nuo Therapeutics AURX +11.64% 33 Beta is -0.1550 as of Jun. 26, 2026. GuruFocus rates AURX with a GF Score™ of 33/100 and a GF Value™ of $4.23 (Possible Value Trap). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Nuo Therapeutics's Beta is -0.1550.


Nuo Therapeutics  (OTCPK:AURX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Nuo Therapeutics Beta Related Terms


Nuo Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Nuo Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuo Therapeutics Beta Chart

Nuo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.91 -509.58 -884.69 -815.86 0.74

Nuo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -795.83 -1.70 0.64 0.74 0.45

AURX vs ACTU, ESLA, LTRN: Beta Comparison

For the Biotechnology subindustry, Nuo Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuo Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's Beta falls into.


AURX
33GF Score
Nuo Therapeutics Inc AURX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuo Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.1550 mean?
Nuo Therapeutics (AURX) has a Beta of -0.1550 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Nuo Therapeutics and its competitors.
Is Nuo Therapeutics' Beta too high?
Nuo Therapeutics' current Beta is -0.1550. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' Beta compare to ACTU and ESLA?
Nuo Therapeutics' Beta of -0.1550 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Nuo Therapeutics and its competitors. Nuo Therapeutics's current Beta is -0.1550. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.23, compared to a current price of $1.01 — trading 76.1% below its estimated fair value. The current Beta is -0.1550. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current Beta is -0.1550 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nuo Therapeutics (AURX) Overvalued in 2026?

Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued. The current stock price of $1.01 is trading 76.1% below its estimated GF Value™ of $4.23. GuruFocus considers Nuo Therapeutics to be Possible Value Trap.

Key valuation signals for AURX:

  • Beta: -0.1550
  • GF Value™: $4.23 vs. price of $1.01 (76.1% below fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nuo Therapeutics Business Description

Address 8285 El Rio Street, Suite 190, Houston, TX, USA, 77054
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score

Get the complete analysis for AURX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.01
Price
$4.23
GF Value